For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? Developed alongs ...

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] Company Overview - Cardinal Health is a leading global healthcare services and products provider, serving nearly 90% of U.S. hospitals and managing over 43,000 pharmaceutical shipments daily [11] - The company operates in multiple segments, including Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution, and offers a wide range of medical and surgical products [11] Investment Ratings - Cardinal Health holds a 2 (Buy) rating on the Zacks Rank, indicating strong potential for investment [12] - The company has a VGM Score of A, suggesting it is an attractive option for investors [12] Growth Potential - Cardinal Health is projected to achieve a year-over-year earnings growth of 14.3% for the current fiscal year, supported by upward revisions in earnings estimates from analysts [12] - The Zacks Consensus Estimate for Cardinal Health's earnings has increased by $0.21 to $9.42 per share [12] Performance Metrics - Cardinal Health has demonstrated an average earnings surprise of +9.2%, indicating a history of exceeding earnings expectations [12] - The combination of a solid Zacks Rank and high Growth and VGM Style Scores positions Cardinal Health as a strong candidate for investors [13]

Group 1 - Cardinal Health Inc. reported third-quarter 2025 adjusted EPS of $2.35, a 13% increase year over year, surpassing the consensus estimate of $2.17 [1] - Sales remained flat at $54.9 billion, missing the consensus of $55.35 billion, while adjusted operating earnings increased by 21% to $807 million [1] - The Pharmaceutical and Specialty Solutions segment's sales were unchanged at $50.6 billion [1] Group 2 - Revenue for the Global Medical Products and Distribution (GMPD) segment rose by 2% to $3.2 billion, driven by volume growth from existing customers [2] - Segment profit increased by 14% to $662 million in the third quarter, supported by brand and specialty products, MSO platforms, and positive generics program performance [6] - The company raised its fiscal year 2025 adjusted EPS guidance from $7.85-$8.00 to $8.05-$8.15, compared to the consensus of $7.96 [3] Group 3 - Cardinal Health anticipates double-digit non-GAAP EPS growth in fiscal 2026 despite evolving macroeconomic conditions [4] - The outlook for the Pharmaceutical and Specialty Solutions segment profit was increased to 11.5% to 12.5% growth, up from a previous range of 10% to 12% [6] - The company expects GMPD segment profit to be consistent with fiscal 2025 segment profit amid macro uncertainty [6] Group 4 - CAH stock is trading 2.30% higher at $144.53 [5] - The company plans to discuss its fiscal 2026 and beyond expectations at its upcoming Investor Day on June 12 [6]